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Purpose: MicroRNAs (miRNAs) are endogenously expressed, small noncoding RNAs that inhibit gene expression by
binding to target mRNAs. Recent studies have revealed that miRNAs function as tumor suppressors or oncogenes. In the
present study, we investigated the role of miRNA-34b/c in uveal melanoma.
Methods: Real-time reverse transcriptase polymerase chain reaction (RT-PCR) was performed to detect the expression
level of miR-34b/c in uveal melanoma cells and primary samples. Subsequently, uveal melanoma cell proliferation was
examined by the MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl] -2H-tetrazolium,
inner salt) assay, clone formation assay, and flow cytometry. Cell apoptosis was measured by caspase3/7 assay. Cell
migration was evaluated by transwell migration assay. The target of miR-34b/c was predicted by bioinformatics and
validated by luciferase assay. In addition, the effect of miR-34b/c on c-Met, cell cycle-related proteins, v-akt murine
thymoma viral oncogene homolog (Akt) and extracellular signal-regulated kinase (ERK) pathway was determined by
western blotting.
Results: miR-34b/c expression, which was dramatically decreased in uveal melanoma cells and clinical samples, can be
upregulated by doxorubicin and epigenetic drugs. The transfection of miR-34b/c into uveal melanoma cells leads to a
significant reduction in cell growth and migration. miR-34b/c caused cell cycle G1 arrest rather than the induction of
apoptosis. Met proto-oncogene (c-Met) was identified as a target of miR-34b/c in uveal melanoma cells. Furthermore,
miR-34b/c was confirmed to downregulate the expression of c-Met, p-Akt, and cell cycle–related proteins by western
blotting.
Conclusions: Our results demonstrate that both miR-34b and miR-34c act as tumor suppressors in uveal melanoma cell
proliferation and migration through the downregulation of multiple targets.
MicroRNAs  (miRNAs)  are  endogenously  expressed,
non-protein-coding RNA molecules with a length of 18–26
nucleotides [1]. These small RNAs directly bind the specific
complementary sequences at the target mRNA (mRNA) 3′
untranslated  regions  (3′  UTRs),  negatively  regulating  the
translation and stability of target mRNAs. Lin-4 was the first
identified  miRNA,  and  is  crucial  in  regulating  the
development  of  Caenorhabditis  elegans  [2].  After  this
discovery, increasing evidence has indicated that miRNAs are
important  regulators  in  diverse  processes  such  as  cell
proliferation, differentiation, development, and tumorigenesis
[3-5].  Aberrant  expression  of  miRNAs  can  lead  to
oncogenesis with the enhancement of cell proliferation and
metastatic potential [6,7]. Some miRNAs are found to act as
oncogenes or tumor suppressor genes. For example, previous
studies  have  revealed  that  let-7  functions  as  a  tumor
suppressor  in  lung  cancer  and  cutaneous  melanoma.  The
decrease of let-7 in lung carcinoma is linked to upregulation
of  the  Ras  oncogene  [8].  In  another  report,  miR-1  and
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miR-206  were  found  to  inhibit  rhabdomyosarcoma  cell
proliferation and migration by targeting met proto-oncogene
(c-Met) [9], which is an important oncogene in many types of
human  cancers,  including  lung  cancer,  hepatocellular
carcinoma, and rhabdomyosarcoma. Recently, the miR-34
family was found to be involved in the p53 tumor suppressor
gene effector network, as direct targets of p53 [10-18]. These
studies imply that miRNAs play key roles in tumorigenesis
through the regulation of cell proliferation, apoptosis, and
migration.
In cases of uveal melanoma, which is the most common
primary intraocular malignancy in adults, there is no effective
treatment  for  patients  with  metastasis  [19].  Thus,  further
investigation of uveal melanoma would be helpful to provide
novel approaches for clinical therapy. Recent research has
linked miRNAs to the development of uveal melanoma. For
example, miR-34a and miR-137 have been demonstrated to
be involved in the tumorigenesis of uveal melanoma [20,21].
Until now, however, the role of miRNAs in uveal melanoma
remains largely unknown.
In the present study, we aimed to investigate the role of
miR-34b/c in uveal melanoma. First, we demonstrate that
miR-34b/c was downregulated in uveal melanoma cells and
clinical  samples.  The  expression  of  miR-34b/c  was
upregulated  by  doxorubicin  (DOX)  and  epigenetic  drugs.
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537Furthermore, the introduction of miR-34b/c into tumor cells
led to the inhibition of growth through cell cycle G1 arrest,
instead of the induction of apoptosis. In addition, miR-34b/c
inhibited cell migration. We also provide evidence that c-
Met was a target of miR-34b/c, and miR-34b/c decreased
endogenous c-Met, phosphorylated v-akt murine thymoma
viral  oncogene  homolog  (p-Akt),  cyclin-dependent  kinase
(CDK) 4, and CDK6 protein levels in uveal melanoma cells.
In  summary,  our  study  demonstrates  that  miR-34b/c  can
function  as  a  tumor  suppressor  in  uveal  melanoma  cell
proliferation and migration.
METHODS
Cell  culture  and  clinical  samples:  The  human  uveal
melanoma  cell  line  SP6.5  was  isolated  from  Caucasian
patients  with  primary  choroidal  melanoma  and  grown  in
Dulbecco  modified  Eagle’s  media  (DMEM;  Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum
(FBS; Hyclone, Logan, UT) and incubated at 37 °C in a
humidified incubator containing 5% CO2, as described [22].
The human primary melanocytes were isolated and cultured
as previously described [23]. Briefly, the uveal stromal tissues
were isolated from donor eye under the dissecting microscope.
The uveal melanocytes were isolated from the uveal stromal
segments by trypsin and collagenase disaggregation. Then the
primary isolated melanocytes were grown in F12 medium
(Invitrogen) supplemented with 10% FBS and incubated at
37 °C in a humidified incubator containing 5% CO2.Five
human  uveal  melanoma  specimens  were  obtained  from
patients  treated  at  the  First  Affiliated  Hospital,  Zhejiang
University (Hangzhou, China), with documented informed
consent in each case. All studies and procedures involving
human tissue were performed in compliance with the Helsinki
Declaration, and approved by the Zhejiang University Ethics
Committee.
Cell proliferation assay: SP6.5 cells were plated at 3×103 cells
per well in 96-well plates (Costar, High Wycombe, UK). For
each well, 50 nM of miR-34b/c mimic molecule (Ambion,
Austin, TX) or a negative control (Ambion) was transfected
into cells using Lipofectamine 2000 (Invitrogen). After 24 h
culture, cell proliferation was measured using the CellTiter 96
Aqueous  MTS  (3-[4,5-dimethylthiazol-2-yl]-5-[3-
carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium,
inner salt) assay (Promega, Madison, WI) according to the
manufacturer’s  instructions.  Briefly,  the  CellTiter  96
AQueous One Solution Reagent was added to each well and
incubated at 37 °C for 3 h. Cell proliferation was determined
by measuring the absorbance at 490 nm using a microtiter
plate reader (Molecular Devices, Sunnyvale, CA).
Flow cytometry analysis: SP6.5 cells were transfected with 50
nM of miR-34b/c mimic or a negative control. After 48 h, the
cells  were  collected,  washed  with  PBS,  and  stained  with
propidium  iodide.  The  stained  cells  (1×105)  were  then
analyzed  for  DNA  content  with  a  flow  cytometer
(FACScaliber; Becton-Dickinson, Franklin Lakes, NJ).
Caspase activity assay: Apoptosis in SP6.5 cells was assessed
using the Caspase-Glo 3/7 Assay kit (Promega) according to
the manufacturer’s instructions. SP6.5 cells were seeded in
96-well  plates  and  transfected  with  50  nM  of  miR-34b/c
mimic or negative control. Cells were then treated with or
without doxorubicin (1 μg/ml) for 48 h. The cells were lysed
and incubated with the caspase substrate for 2 h, followed by
reading  by  a  microtiter  plate  reader  (Molecular  Devices,
Sunnyvale, CA).
Transwell migration assays: SP6.5 cells were grown to ~70%
confluence and transfected with 50 nM miR-34b/c mimic or
a negative control. After 24 h, the cells were harvested by
trypsinization and washed once with PBS (Invitrogen). To
detect  cell  migration,  8  mm  pore  size  culture  inserts
(Transwell; Costar, High Wycombe, UK) were placed into the
wells of 24-well culture plates, separating the upper and lower
chambers. In the lower chamber, 400 μl of DMEM containing
hepatocyte growth factor (HGF; 20 ng/ml; R&D Systems,
Minneapolis, MN) was added. Then, 1×105 cells were added
to the upper chamber. After 24 h of incubation at 37 °C with
5% CO2, the number of cells that had migrated through the
pores  was  quantified  by  counting  five  independent  visual
fields under the microscope (Zeiss, Oberkochen, Germany)
using a 20× objective. Cells were stained with hematoxylin
and eosin for observation.
miR-34b/c target prediction: TargetScan was conducted for
miR-34b/c  target  prediction.  TargetScan  predicts  miRNA
targets by searching for the presence of conserved 8-mer and
7-mer sites that match the seed region of each miRNA [24].
The possible potential target mRNAs, as well as the potential
binding sites of miR-34b/c, were predicted by the TargetScan
program.
Luciferase reporter assays: The Luciferase reporter vectors
were constructed as previously reported [20]. Briefly, Human
c-Met 3’UTR was amplified by PCR, using human genomic
DNA as template. The PCR product was cloned into pMIR-
REPORT vector (Ambion).  The recombinant plasmid was
named pLuc-MET 3’UTR. The pLuc-MET 3’UTR Mutant
plasmid was generated by changing the seed region sequence
from  CACUGCC  to  GUGACGG,  using  QuickchangeXL
Mutagenesis Kit (Stratagene, LaJolla, CA).SP6.5 cells were
cotransfected with 0.4 μg of firefly luciferase reporter vector
and 0.02 μg of the control vector, pRL-SV40 (Promega), using
Lipofectamine 2000 (Invitrogen) in 24-well plates (Costar).
Each transfection was performed in four wells. For each well,
50 nM of miR-34b, miR-34c mimic, or a negative control was
cotransfected with the reporter constructs. Luciferase assays
were  performed  24  h  after  transfection  using  the  Dual
Luciferase Reporter Assay System (Promega). The Renilla
luciferase activity was used to normalize the firefly luciferase
activity.
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538Western blot analysis: SP6.5 cells (1×105) were seeded and
grown in DMEM with 10% FBS in 60 mm dishes for 24 h.
After  transfection,  the  cells  were  washed  with  PBS  and
subjected to lysis in a lysis buffer (50 mM/l Tris-Cl, 1 mM/l
EDTA, 20 g/l sodium dodecyl sulfate, 5 mM/l dithiothreitol,
10  mM/l  phenylmethylsulfonyl  fluoride).  Protein  lysates
(50 μg each) were separated by 10% sodium dodecyl sulfate
–PAGE, then electrotransferred to nitrocellulose membranes.
The membranes were blocked in the buffer containing 5%
nonfat  milk  in  PBS  with  0.05%  Tween-20  for  2  h,  and
incubated  overnight  with  primary  antibody  at  4  °C.  The
membranes were washed twice with PBS containing 0.05%
Tween-20,  then  incubated  with  peroxidase-conjugated
secondary antibodies and developed with an electrogenerated
chemiluminescence  detection  kit  (Pierce,  Rockford,  IL).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as a loading control. All the antibodies, including c-Met,
total  extracellular  signal-regulated  kinase  1/2  (ERK1/2),
phosphorylated  ERK1/2,  total  Akt,  phosphorylated  Akt,
cyclin-dependent  kinase  4  (CDK4),  CDK6,  and
phosphorylated  retinoblastoma  1  (Rb)  were  from  Cell
Signaling Technology (Beverly, MA).
Statistical analysis: All data are shown as the mean±standard
error of the mean. Differences between groups transfected
with miR-34b/c and a negative control were analyzed using
the Student t test. Statistical significance was accepted at
p<0.05.
RESULTS
MicroRNA-34b/c  expression  was  downregulated  in  uveal
melanoma  cells  and  specimens:  To  investigate  whether
miR-34b/c  was  involved  in  the  tumorigenesis  of  uveal
melanoma, we first examined miR-34b/c expression levels in
primary  samples.  Real-time  reverse  transcriptase  (RT)-
polymerase chain reaction (PCR) analysis was performed to
detect  miR-34b/c  expression  in  five  specimens  of  uveal
melanoma. The adjacent uveal tissue was used as normal
control in each case. As a result, miR-34b/c expression was
dramatically  decreased  in  specimens  1,  2,  and  5,  and
undetectable  in  specimens  3  and  4,  in  contrast  to  normal
tissues  (Figure  1A).  We  also  compared  the  expression  of
miR-34b/c in uveal melanoma cell line SP6.5 and primary
uveal melanocytes by real-time RT–PCR. Consistent with the
results from primary samples, miR-34b/c was expressed in
uveal melanocytes, but was dramatically decreased in the
SP6.5  cell  line  (Figure  1B).  These  results  indicate  that
miR-34b/c expression is frequently downregulated in human
uveal melanoma.
Figure 1. MicroRNA-34b/c expression
was  downregulated  in  human  uveal
melanoma cell line and clinical samples.
A: Real time reverse transcriptase (RT)-
PCR analysis was performed to detect
the expression of miR-34b/c in clinical
samples.  The  value  for  miR-34b/c  in
normal uveal tissue was set at 1, and the
relative amounts of miR-34b/c in tumor
tissues were shown as fold induction.
Both  miR-34b  and  miR-34c  were
dramatically  decreased  in  five
specimens  as  compared  with  normal
tissues. N: normal uveal tissue; T: tumor
tissue. B: The expression of miR-34b/c
was measured by real time RT–PCR in
uveal melanoma cell line SP6.5, as well
as  the  primary  uveal  melanocytes.
miR-34b/c  was  expressed  in  uveal
melanocytes but dramatically decreased
in  uveal  melanoma  cells.  U6  snRNA
was used as an internal control.
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539MicroRNA-34b/c  expression  was  upregulated  in  uveal
melanoma  cells  treated  with  DOX  or  epigenetic  drugs:
Treatment  of  tumor  cells  with  DOX  (doxorubicin)  or
inhibitors  of  DNA  methyltransferases  and/or  histone
deacetylase  suppresses  cell  growth  by  activating  multiple
tumor suppressor genes [25-27]. We detected the expression
levels of miR-34b/c in SP6.5 cells treated with either DOX,
5-aza-dC (a DNA hypomethylating agent), and/or TSA (a
histone  deacetylase  inhibitor).  Expression  of  miR-34b/c
increased after treatment with DOX at 24 h, with maximal
induction at 48 h (Figure 2A). Similarly, miR-34b/c was also
upregulated by 5-aza-dC or TSA (Figure 2B). Furthermore,
the  effect  of  drug  combination  seems  to  be  additive  on
miR-34b/c  expression  (Figure  2B).  Overall,  these  results
demonstrated  that  the  expression  of  miR-34b/c  in  uveal
melanoma cells can be affected by DOX and epigenetic drugs.
MicroRNA-34b/c inhibited uveal melanoma cell proliferation
and  induced  G1  cell  cycle  arrest:  After  determining  the
miR-34b/c expression pattern, we sought to investigate the
effects on uveal melanoma cells by restoration of miR-34b/c.
SP6.5 cells were transfected with either the miR-34b/c mimic
or a negative control. After transfection, the MTS assay was
performed to assess cell numbers at days 1 to 5. MiR-34b/c
caused a dramatic inhibition of cell proliferation in SP6.5
uveal melanoma cells over a five-day interval (Figure 3A) as
compared with the negative control. We detected a decrease
of cell numbers in the SP6.5 cell line by day 2 following
transfection,  and  the  growth  of  cells  transfected  with  the
miR-34b/c mimic was statistically significantly retarded, as
compared with the negative control. A significant reduction
in cell number persisted through day 5 (48.85±5.39% decrease
for miR-34b and 61.72±3.6% for miR-34c, p<0.01, Figure
Figure  2.  MicroRNA-34b/c  was
upregulated  by  doxorubicin  and
epigenetic drugs. A: Real time reverse
transcriptase  (RT)-PCR  analysis  was
performed to detect the expression of
miR-34b/c in uveal melanoma cell line
SP6.5, after treatment with DOX for 24
h and 48 h. B: SP6.5 cells were treated
with 5-aza-dC at 1 μM or 5 μM alone,
TSA (100 ng/ml) alone, or combinations
of both. miR-34b/c expression level was
determined by Real-time RT–PCR. The
value  for  miR-34b/c  in  SP6.5  cells
without any treatment was set at 1, and
the  relative  amounts  of  miR-34b/c  in
cells treated with drugs were shown as
fold induction. U6 snRNA was used as
an internal control.
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5403A). With clone formation assay, we were able to visually
depict the growth retardation effect of miR-34b/c on SP6.5
cells by crystal violet staining after 7 days of culture (Figure
3B).  The  mechanism  by  which  miR-34b/c  inhibited  cell
growth was attributed to induction of G1 cell cycle arrest.
Forty-eight hours after transfection, cell were stained with
propidium iodide and analyzed by flow cytometry. In cells
transfected with miR-34b, 73.22% of cells accumulated in
G1 compared with 59.71% of cells for the negative control. In
cells transfected with miR-34c, 80.76% of cells accumulated
in G1 compared with 59.71% of cells for the negative control
(Figure 3C). These results indicate that miR-34b/c inhibits cell
proliferation and plays an important role in regulating uveal
melanoma cell cycle G1 phase.
MicroRNA-34b/c enhanced uveal melanoma cell sensitivity to
DOX:  To  further  characterize  the  miR-34b/c-mediated
inhibition of cell growth, we examined caspase activity to
determine  if  apoptosis  was  also  involved.  No  significant
difference  in  caspase  3/7  activity  was  observed  between
miR-34b/c transfected cells and negative control transfected
cells (Figure 4A). Thus, these analyses indicate that miR-34b/
c inhibited uveal melanoma cell growth by cell cycle G1 arrest
rather than by inducing apoptosis. After 48 h, caspase 3/7
activity was significantly increased in miR-34b/c-transfected
cells in comparison to negative control after DOX treatment
(Figure 4B), which suggested that miR-34b/c enhanced cell
sensitivity to DOX.
MicroRNA-34b/c inhibited uveal melanoma cell migration:
We next evaluated the effect of miR-34b/c on uveal melanoma
cell  migration  by  transwell  migration  assay.  Following
transfection  with  either  miR-34b/c  mimic  or  a  negative
control, SP6.5 cells were seeded on cultured inserts and the
ability of cells to migrate to the underside of the inserts was
assessed in the presence of HGF. As shown in Figure 5, the
migration  of  cells  transfected  with  miR-34b/c  was
significantly  inhibited,  as  compared  with  negative  control
(208±15 for NC, 122±10 for miR-34b, 116±9 for miR-34c,
n=3 each, p<0.01). Therefore, the introduction of miR-34b/c
caused reduced cell migration in response to HGF.
c-Met  was  a  target  of  microRNA-34b/c:  To  explore  the
molecular mechanisms underlying miR-34b/c mediated cell
proliferation and migration, we used TargetScan for miR-34b/
c target prediction. As shown in the Figure 6A, two potential
binding sites of miR-34b/c, as well as the miR-34b/c: mRNA
pairing model, were predicted in the 3′ UTR of the c-Met
mRNA (Figure 6A). To examine the specific regulation of c-
Met through the two predicted binding sites, we cloned the c-
Met 3′ UTR into the pMIR-REPORT vector (Figure 6B). As
expected, the luciferase activity of the wild-type pLuc-MET
3′ UTR construct was significantly suppressed following the
transfection of miR-34b/c into SP6.5 cells, in contrast to the
negative  control  (Figure  4C).  Mutations  of  the  two  8  bp
binding sites in c-Met 3′ UTR completely abolished miR-34b/
c-mediated inhibition of luciferase activity (Figure 6C). These
results  demonstrated  that  c-Met  was  a  direct  target  of
miR-34b/c.
Introduction  of  microRNA-34b/c  downregulated  c-Met,  p-
Akt,  and  cell  cycle–related  proteins:  To  confirm  that
miR-34b/c was indeed responsible for the downregulation of
c-Met in uveal melanoma cells, SP6.5 cells were transfected
Figure  3.  Ectopic  microRNA-34  b/c
inhibited  SP6.5  cell  proliferation.  A:
MTS  cell  proliferation  assay  was
performed on days 1 to 5 as indicated
after transfection into SP6.5 cells with
either miR-34 b/c mimic or a negative
control  (NC).  Results  represent  those
obtained in three experiments. B: SP6.5
cells transfected with miR-34b/c or NC
were  seeded  at  low  density.  Colony
formation  was  observed  by  staining
with  crystal  violet  after  seven  days.
Typical results from three independent
experiments are depicted. C: SP6.5 cells
were transfected with miR-34b/c or NC.
After 48 h, cells were collected, stained
with propidium iodide, and analyzed by
flow  cytometry.  The  most
representative  results  from  three
independent experiments are shown.
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541with  the  miR-34b/c  or  a  negative  control.  As  expected,
western  blot  analysis  showed  that  c-Met  expression  was
dramatically decreased in the cells transfected with miR-34b/
c,  as  compared  to  negative  control  (Figure  7).  Next,  we
examined the expression patterns of ERK1/2 and Akt after
downregulation of c-Met by miR-34b/c. As shown in Figure
7A,  miR-34b/c  caused  a  significant  reduction  of
phosphorylated Akt in SP6.5 cells, but had no obvious effect
on ERK1/2 phosphorylation. Neither total Akt nor ERK1/2
expression changed significantly (Figure 7A).
In addition to the effects on c-Met and p-Akt, we also
examined the expression of cell cycle–related proteins after
transfection with miR-34b/c into SP6.5 cells. As indicated,
CDK4, CDK6, and phosphorylated retinoblastoma protein (p-
Rb) were dramatically decreased in miR-34b/c-transfected
cells (Figure 7B). Thus, miR-34b/c also downregulated cell
cycle regulatory proteins in SP6.5 cells (Figure 7B).
Figure 4. Transfection of microRNA-34
b/c did not induce cell apoptosis but did
enhance  cell  sensitivity  to  DOX.
Caspase  3/7  activity  assay  was
performed  on  SP6.5  cells  transfected
with  either  miR-34b/c  or  a  negative
control  (NC).  Relative  caspase  3/7
activity is indicated in comparison to the
negative  control.  Cells  were  treated
without (A) or with DOX (B). Results
represent  those  obtained  in  three
experiments.
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542DISCUSSION
Recent evidence has revealed that miRNA plays a central role
in tumorigenesis through the regulation of cell proliferation
and migration. Until now, however, only several reports about
miRNAs in uveal melanoma have been published. miR-34a
has been demonstrated to be regulator of c-Met oncogene and
inhibit  cell  proliferation  and  migration  [20].  In  addition,
miR-137 has been found to suppress uveal melanoma cell
growth by targeting MITF and CDK6 [21]. Previous studies
have identified miR-34b/c as a direct transcriptional target of
p53 and an important component of the tumor suppressor
network,  which  operates  by  modulating  cell  cycle
progression, DNA repair, and apoptosis [10,13]. miR-34b/c is
also important in various types of cancer [28-31]. So far,
however, little is known about the function of miR-34b/c in
uveal melanoma.
To investigate the role of miR-34b/c in uveal melanoma,
we  first  examined  miR-34b/c  expression  in  this  case.
miR-34b/c,  expressed  in  normal  uveal  melanocytes,  is
downregulated  in  both  uveal  melanoma  cells  and  tumor
specimens (Figure 1). Similarly, a previous study has revealed
that  miR-34a  is  absent  in  uveal  melanoma  cell  lines  and
clinical specimens [20]. The activation of miR-34b/c by 5-
aza-dC and TSA indicates that the epigenetic mechanism is
responsible  for  the  miR-34b/c  downregulation  in  uveal
melanoma cells. In addition, miR-34b/c can be dramatically
upregulated by DOX, which provides another way to activate
miR-34b/c in uveal melanoma.
Transfection of miR-34b/c into uveal melanoma cells
inhibited cell cycle G1 arrest and led to significant growth
retardation (Figure 3). In contrast to other reports, our results
indicated that miR-34b/c did not induce uveal melanoma cell
apoptosis directly, but rather enhanced the cell sensitivity to
DOX. In addition to cell proliferation and migration, aberrant
miRNAs have also been shown to affect tumor cell migration.
For example, it has been reported that miR-21 enhanced tumor
invasion  and  metastasis  in  hepatocellular  cancer  through
regulation of phosphatase and tensin homolog (PTEN) [32],
an important tumor suppressor in various types of carcinomas.
Here,  we  demonstrated  that  miR-34b/c  can  inhibit  uveal
melanoma  cell  migration  dramatically  in  an  hepatocyte
growth factor (HGF)-dependent fashion.
The tyrosine kinase receptor c-Met is an important proto-
oncogene that is upregulated in a variety of cancers [33,34].
c-Met activation, through its ligand HGF, can lead to tumor
growth, invasiveness, and metastasis [34-37]. Therefore, we
examined the effect of miR-34b/c on c-Met expression and its
pathway in uveal melanoma cells. A few miRNAs have been
discovered to regulate c-Met expression, such as miR-34a,
miR-1/206,  and  miR-199a*  [9,20,38].  In  this  study,  we
demonstrated  that  the  other  two  members  of  the  miR-34
family—miR-34b and miR-34c—play an important role in
uveal melanoma cell proliferation and migration with their
effects related to the c-Met signaling pathway. In a previous
study,  it  was  demonstrated  that  the  PI3K/Akt  signaling
pathway was involved in HGF-induced migration of uveal
melanoma cells through the activation of c-Met [35]. As c-
Met  expression  is  directly  regulated  by  miR-34b/c,  its
downstream effects are similarly altered in uveal melanoma
cells.
In addition to regulation of c-Met activity, introduction
of  miR-34b/c  downregulated  cell  cycle–related  proteins,
including p-Rb, CDK4, and CDK6. Both CDK4 and CDK6
are important kinases that play an essential role in G1 phase
progression  of  the  cell  cycle  [39].  Moreover,  CDK4  and
CDK6 have been proved to be overexpressed in cutaneous
Figure 5. Transfection of microRNA-34
b/c  reduced  uveal  melanoma  cell
migration. Transwell migration assay of
uveal  melanoma  cell  lines  was
performed. SP6.5 cells were transfected
with miR-34b/c or a negative control
(NC) for 24 h and plated on cultured
inserts in DMEM containing 20 ng/ml
of hepatocyte growth factor (HGF) to
assess  the  number  of  migrating  cells.
The number of cells that had migrated
through  the  pores  was  quantified  by
counting 10 independent visual fields
using  a  20×  microscope  objective.  *:
Differences in cell migration between
miR-34b/c  and  negative  control
transfected  cells  were  significant,
p<0.01.
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543melanoma,  which  suggests  a  possible  role  in  melanoma
development  [40,41].  Rb  was  first  discovered  as  a  tumor
suppressor gene, and has a central role in cell cycle regulation
and tumorigenesis through control of the G1-S transition in
proliferating cells [42]. The downregulation of CDK4 and
CDK6 (Figure 7B), which downregulates Rb in turn, supports
the notion that miR-34b/c can also inhibit cell proliferation
through cell cycle protein regulation.
In a previous study of miR-34a in uveal melanoma, it was
discovered  that  miR-34a  silence  in  uveal  melanoma,
furthermore,  miR-34a  inhibited  cell  proliferation  and
migration by targeting c-Met. However, some details of the
function of miR-34a remain unclear. In this study, we also
demonstrated  that  downregulation  of  miR-34b/c  in  uveal
melanoma,  miR-34b/c  suppressed  cell  proliferation  and
migration by targeting c-Met. Moreover, we have provided
strong evidence that miR-34b/c suppressed cell growth by
inhibition of cell cycle G1 arrest rather than the induction of
apoptosis. In addition, we employed multiple approaches to
reactivate  miR-34b/c,  including  the  use  of  5-aza-dC,
trichostatin A (TSA), and DOX.
To sum up, our results showed a low level of miR-34b/c
expression in uveal melanoma, and provided the approaches
to activate miR-34b/c. Restoration of miR-34b/c resulted in
the inhibition of cell growth and migration. Specifically, we
demonstrated the molecular mechanism of miR-34b/c in the
modulation  of  uveal  melanoma  cell  proliferation  and
migration.  miR-34b/c  targeted  c-Met,  which  in  turn
downregulated  the  downstream  Akt  signaling  pathway,
leading to the inhibition of cell proliferation and migration. In
addition,  miR-34b/c  suppressed  cell  proliferation  via  cell
cycle proteins CDK4, CDK6, and Rb. Taken together, our
findings suggest that miR-34b/c may play an important role
in controlling the carcinogenesis of uveal melanoma.
Figure  6.  c-Met  was  a  target  of
microRNA-34  b/c.  A:  Two  specific
binding sites of miR-34b/c in the c-Met
3′  untranslated  region  (UTR)  was
marked  with  black  color.  Alignment
between the predicted miR-34b/c target
sites and miR-34b/c, the common 8 bp
seed  sequence  for  miR-34b/c:mRNA
(mRNA) pairing is shown. B: Design of
the pMIR luciferase reporter constructs,
containing c-Met 3′ UTR, which was
used to verify the putative miR-34b/c
binding  sites.  C:  SP6.5  cells  were
cotransfected  with  miR-34b/c,  pLuc-
MET 3′ UTR, and a pRL-SV40 reporter
plasmid.  The  luciferase  activity  was
measured  after  24  h.  Values  are
presented as relative luciferase activity
after normalization to Renilla luciferase
activity.  *:  Differences  in  luciferase
activity  between  miR-34b/c  and
negative control transfected cells were
significant, p<0.01.
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